GERD

Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market

Retrieved on: 
Giovedì, Ottobre 19, 2023
Gastroenterology, Exhibition, Rare, Booth, Hall, GERD, Fira (Barcelona Metro), Partnership, Daewoong Pharmaceutical, Autoimmunity, Pain management, Pharmaceutical industry

SEOUL, South Korea, Oct. 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world's premier pharmaceutical industry exhibitions.

Key Points: 
  • SEOUL, South Korea, Oct. 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world's premier pharmaceutical industry exhibitions.
  • The event is scheduled to take place from the 24th to the 26th of October at Fira Barcelona Gran Via, Spain.
  • Especially, Daewoong Pharmaceutical will accelerate to build partnership with global partner for their own novel drug such as GERD treatment (ingredient: Fexuprazan) and Diabetes treatment (ingredient: Enavogliflozin).
  • Additionally, the company has entered into technology export agreements with 18 countries, including China, further solidifying its global reach.

Implantica's RefluxStop™ made a substantial impact at the American Foregut Society (AFS)

Retrieved on: 
Martedì, Ottobre 10, 2023
Annual general meeting, General surgery, Esophagus, AFS, Division, European, Deutsche Medizinische Wochenschrift, University, University of Southern California, CEST, Dysphagia, Gastroenterology, CE, University of Milan, Associate, Surgeon, Certification, Clinic, Patient, Gastroesophageal reflux disease, Hiatal hernia, Dentistry, Hospital, GERD

), a medtech company at the forefront of bringing advanced technology into the body, successfully attended the American Foregut Society (AFS) 2023 Annual Meeting held in Dallas, Texas.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, successfully attended the American Foregut Society (AFS) 2023 Annual Meeting held in Dallas, Texas.
  • The meeting included a panel discussion on RefluxStop with 4 leading European KOLs and was moderated by the former president of AFS.
  • The panel reviewed and discussed the promising outcomes data from over 500 RefluxStop procedures performed in Europe.
  • "It is rewarding that outcomes achieved during the CE study can be replicated in a real-world setting.

SonarMD, Telebelly Health Team Up to Deepen Support for Gastroenterology Practices

Retrieved on: 
Sabato, Ottobre 7, 2023
Constipation, Mid-level practitioner, Algorithm, Partnership, Hospital, Health, Diarrhea, Friction, Dysphagia, Gastroenterology, Colorectal cancer, Delays, APP, GERD, Patient, Quality of life, Nursing, GI

CHICAGO, Oct. 7, 2023 /PRNewswire-PRWeb/ -- SonarMD, the company leading value-based care enablement in digestive health, and Telebelly Health, a specialized virtual care platform for gastroenterology (GI) practices, today announced a new partnership that offers practices using SonarMD access to Telebelly Health's services.

Key Points: 
  • CHICAGO, Oct. 7, 2023 /PRNewswire-PRWeb/ -- SonarMD , the company leading value-based care enablement in digestive health, and Telebelly Health, a specialized virtual care platform for gastroenterology (GI) practices, today announced a new partnership that offers practices using SonarMD access to Telebelly Health's services.
  • "Together we make it easy for GI practices to serve more patients and optimize the patient experience, while positioning practices to thrive in a digital, value-based future."
  • This non-exclusive collaboration brings together two physician-founded companies focused on addressing the most prevalent barriers to GI care.
  • "We are thrilled to join forces with SonarMD to help GI practices adopt transformative models of care delivery," said Sheri Rudberg, CEO and co-founder of Telebelly Health.

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Retrieved on: 
Martedì, Settembre 26, 2023
Vonoprazan, Food and Drug Administration, NDA, Stomach, GERD, NERD, Patient, Heartburn, FDA, Food, Safety, Pharmaceutical industry

The regulatory submission is supported by the positive data from the PHALCON-NERD-301 study, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults with Non-Erosive GERD (NERD).

Key Points: 
  • The regulatory submission is supported by the positive data from the PHALCON-NERD-301 study, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults with Non-Erosive GERD (NERD).
  • Vonoprazan is an investigational first-in-class potassium-competitive acid blocker (PCAB) from a novel class of medicines that block acid secretion in the stomach.
  • Phathom expects a 10-month regulatory review and if approved, anticipates a third quarter 2024 U.S. launch for vonoprazan as a daily treatment for Non-Erosive GERD.
  • Phathom also plans to initiate an additional Phase 3 study to evaluate vonoprazan as an As Needed treatment for episodic heartburn relief in adults with Non-Erosive GERD, a novel dosing treatment regimen.

Tampa General Hospital Named "Best in Class" by WebMD Choice Awards

Retrieved on: 
Mercoledì, Settembre 20, 2023
WebMD, U.S. News & World Report Best Hospitals Rankings, Hospital, Perception, Colorectal surgery, Stomach cancer, GERD, U.S. News & World Report, Patient, Practitioner, Physician, Sleep disorder, Tampa General Hospital, TGH, Neurology, News, Nursing, Orthopedic surgery

TAMPA, Fla., Sept. 20, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) earned top honors in this year's WebMD Choice Awards. The academic health system is one of 26 health systems across the nation to receive the WebMD Elite Choice Award, which honors systems that patients and providers prefer 2:1 over competitors.

Key Points: 
  • TAMPA, Fla., Sept. 20, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) earned top honors in this year's WebMD Choice Awards.
  • "This national recognition by patients and providers as the region's preferred hospital is a testament to the exceptional care we offer at Tampa General Hospital," said John Couris, president and CEO of Tampa General.
  • In 2023, WebMD honored 167 health systems, and 26 recipients earned the WebMD Elite Choice Award, including Tampa General.
  • The WebMD recognition comes just weeks after Tampa General was named the #1 hospital in Tampa Bay by the 2023-2024 U.S. News & World Report's Best Hospitals , an honor TGH has earned for six consecutive years.

Vivante Health Closes $31 Million Series B Round to Advance Digital Digestive Health Platform

Retrieved on: 
Mercoledì, Settembre 20, 2023
Food, Venture round, Health, Quality of life, Prescription, Gastroenterology, GERD, Fortune 500, Patient, IBS, Nursing, Diagnosis, Growth, Inflammatory bowel disease, ROI, GI, Pharmaceutical industry, Health insurance, Vivante Corporation

CHICAGO, Sept. 20, 2023 /PRNewswire/ -- Vivante Health, the leader in digital digestive health, today announced the closing of $31 million in Series B funding led by new investor Mercato Partners. The round also includes new capital from Health Catalyst Capital as well as returning investors 7wireVentures, Intermountain Ventures, Distributed Ventures, Human Capital, and SemperVirens, reflecting the proven ability of Vivante's GIThrive platform to improve patient outcomes at scale and reduce medical costs in an area that typically ranks among an organization's top five healthcare expenses. 

Key Points: 
  • CHICAGO, Sept. 20, 2023 /PRNewswire/ -- Vivante Health , the leader in digital digestive health, today announced the closing of $31 million in Series B funding led by new investor Mercato Partners.
  • The latest investment brings the total capital raised by Vivante to date to $47 million, following a $16 million Series A round in late 2021.
  • The Series B capital will support continued technology upgrades designed to predict the onset and progression of GI conditions and provide complete virtual care for digestive disorders.
  • "We are thrilled to have the support of industry-leading capital partners as we execute on our vision at Vivante," said Bill Snyder, Vivante Health CEO.

18.0% CAGR Growth Expected in the Global Single Use-Disposable Endoscopes Market: Meeting Clinical Needs with Innovative Solutions - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Settembre 8, 2023
Medical Supplies, Health, Fungal infection, Dentistry, ENT, COPD, Stenosis, Single, Bleeding, Urinary tract infection, Prevalence, HAI, Hospital, Bronchoscopy, Bronchoscopic lung volume reduction, Cancer, Inflammation, Compound annual growth rate, GERD, Incidence, Anemia, Conditional sentence, Growth, Ulcer, FDA, Medical device, Endoscopy

Its minimally invasive nature enhances patient comfort, facilitating early detection and interventions that can potentially lead to improved outcomes.

Key Points: 
  • Its minimally invasive nature enhances patient comfort, facilitating early detection and interventions that can potentially lead to improved outcomes.
  • The Single Use-Disposable Endoscopes Market is predicted to witness a Compound Annual Growth Rate (CAGR) of 18.04% from 2022 to 2030.
  • Regulatory approvals, like the recent FDA endorsement for innovative disposable endoscopes designed for sterile procedures, are driving sales.
  • Increased awareness and cost-effective options drive the demand for single use disposable endoscopes in the region.

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

Retrieved on: 
Lunedì, Agosto 21, 2023
Maintenance, Esophagitis, Symantec Endpoint Protection, NVP, NDA, Gastroesophageal reflux disease, Tablet, GERD, Vonoprazan, PDUFA, CRL, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Dietary supplement, Pharmaceutical industry

The additional stability was required for the FDA to complete its NDA review for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis.

Key Points: 
  • The additional stability was required for the FDA to complete its NDA review for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis.
  • Phathom resubmitted the NDA for vonoprazan for Erosive GERD in May 2023 on the basis of three months of stability data and was assigned a PDUFA goal date of November 17, 2023.
  • “The latest stability data confirm that our minor product reformulation has limited the presence of NVP, and we believe these data comfortably support the proposed shelf life for vonoprazan tablets.
  • If approved, a combined U.S. commercial launch for Erosive GERD and H. pylori is planned for the fourth quarter of 2023.

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

Retrieved on: 
Giovedì, Agosto 10, 2023
Hercules, New Drug Application, Clinical trial, PAS, NDA, Prescription Drug User Fee Act, QD, Gastroesophageal reflux disease, Tablet, Chemistry, GERD, Patient, Vonoprazan, PDUFA, CRL, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clarithromycin, Food, Safety, Pharmaceutical industry, Video game, Bank, Amoxicillin

Second Quarter 2023 Financial Results:

Key Points: 
  • Second Quarter 2023 Financial Results:
    Net loss for the second quarter ended June 30, 2023, was $41.0 million, compared to $50.9 million for second quarter 2022.
  • Second quarter 2023 net loss included a non-cash charge related to stock-based compensation of $7.3 million compared to $5.9 million for second quarter 2022.
  • Research and development expenses for the second quarter 2023 were $12.8 million, a decrease of $6.0 million compared to $18.8 million for second quarter 2022.
  • General and administrative expenses for the second quarter 2023 were $18.9 million, a decrease of $7.6 million compared to $26.5 million for second quarter 2022.

Daewoong Pharmaceutical's Fexuprazan takes its first step into Africa Entering into a partnership with Cooper Pharma, the No. 1 pharmaceutical company in Morocco in the field of digestive health

Retrieved on: 
Lunedì, Luglio 24, 2023
Agreement, Half-life, Gastric acid, Sale, Gastroesophageal reflux disease, GERD, PPI, Pharmaceutical industry, Daewoong Pharmaceutical

The partnering company is Cooper Pharma, a leading Moroccan pharmaceutical company with presence in Africa and Middle East.

Key Points: 
  • The partnering company is Cooper Pharma, a leading Moroccan pharmaceutical company with presence in Africa and Middle East.
  • Cooper Pharma, founded in 1933, has rapidly expanded its businesses in the pharmaceutical industry, keeping its number one ranking position in Morocco's PPI market, which was estimated to be around KRW75.5 billion in revenue last year.
  • Daewoong intends to propose a new innovative solution to GERD drugs building on Cooper Pharma's significant market dominance and network.
  • By entering into this Agreement, Daewoong Pharmaceutical plans to expand its presence of P-CAB drug Fexuprazan in the African pharmaceutical market for gastroesophageal reflux disease (GERD).